Health · 35 views
FDA expands use of Zoryve to include young children with plaque psoriasis
The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older.
Summary
The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older. The expanded approval was granted to Arcutis Biotherapeutics.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Scientists propose national microbiome plan to prevent chronic diseaseContinue reading
- Study finds patients experienced rapid weight gain after starting antipsychotic medicationContinue reading
- Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease RiskContinue reading
- Anxiety builds over Medicaid work requirementsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow